Courtroom, meet CMS
MMJ International Holdings says it’s officially jumping into federal litigation challenging CMS’s Substance Access Beneficiary Engagement Incentive program. The company is asking for a preliminary injunction and a stay of agency action, with a hearing scheduled for May 1 in Washington, D.C.
Why this matters
If you’re building a business around a government-backed healthcare program, you really want the government to be, well, on your side. A court-ordered pause could buy MMJ time and keep the CMS pilot from moving forward as planned.
The investor angle
This isn’t some random headline-chasing lawsuit. It’s a policy fight with real business implications:
- If MMJ wins the injunction, the program could be delayed or frozen.
- If it loses, CMS gets a clearer runway to keep the pilot rolling.
- Either way, the legal process now becomes part of the investment story, which is never ideal when you’d rather be talking about product and revenue.
Big picture: when your growth thesis depends on federal rules, a courtroom date can matter just as much as a product launch.